Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
821-840 of 2,120 trials

Advanced Non-Small Cell Lung Cancer: New Immunotherapy Combinations

We are evaluating new combinations of immunotherapy for adults with untreated advanced non-small cell lung cancer. The goal is to see if these combinations are safe and more effective than standard treatment.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Non-Small Cell Lung Cancer: Cemiplimab Immunotherapy Study

We are investigating if continuing cemiplimab treatment helps patients with oligometastatic NSCLC live longer without disease progression after initial therapy. This study compares the effects of cemiplimab to a placebo.

Non-small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)Standard MedicinesOncology

Chronic Rhinosinusitis: Lebrikizumab Study

We are testing a new medication, lebrikizumab, for people with chronic rhinosinusitis and nasal polyps who are already using nasal corticosteroids. The study aims to see if it can improve nasal congestion and reduce polyp severity.

Chronic Rhinosinusitis with Nasal Polyps1-2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Ovarian Stimulation Methods for Embryo Accumulation

We are comparing two approaches to ovarian stimulation in patients preparing for embryo testing. The goal is to see if one method produces more healthy embryos than the other.

Female InfertilityMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Sedation in Preterm Infants: Dexmedetomidine vs. Midazolam

We are comparing two sedation methods for very preterm infants on mechanical ventilation to see which one helps with extubation time and overall safety. This study will help us understand the best approach for sedation in these vulnerable patients.

Infant Sedation>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPediatrics

Triple-Negative Early Breast Cancer: Sacituzumab Govitecan with or without Pembrolizumab

We are comparing two treatment options for low-risk, triple-negative early breast cancer to see which is more effective. The study also evaluates how these treatments affect patients' quality of life.

Triple-Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Ulcerative Colitis and Crohn’s Disease: Vedolizumab for Kids

We are studying the long-term safety of vedolizumab in children with ulcerative colitis or Crohn’s disease. The trial also looks at how this treatment affects their quality of life and related health events.

Ulcerative ColitisCrohn's Disease1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Familial Chylomicronemia Syndrome: AKCEA-APOCIII-LRX Study

We are testing a new subcutaneous treatment for patients with Familial Chylomicronemia Syndrome who have previously used volanesorsen. The study aims to evaluate its safety and how well it is tolerated.

Familial Chylomicronemia Syndrome>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyHematology

Perennial Allergic Rhinitis: Lebrikizumab Study

We are testing a new medication, lebrikizumab, to see if it helps adults with perennial allergic rhinitis experience fewer nasal symptoms. This study compares its effects to a placebo treatment.

Perennial Allergic RhinitisConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteAllergologyOtolaryngologyPulmonology

Diabetic Kidney Disease: Hyperpolarized MRI Study

We are investigating a new MRI technique to see if it can help classify the progression of diabetic kidney disease. This study aims to improve understanding of kidney function and metabolism in affected individuals.

Diabetic Kidney Disease>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyNephrology

Knee Osteoarthritis: Genicular Arteries Embolization Study

We are investigating whether a new procedure can help reduce knee pain in people with symptomatic knee osteoarthritis. Participants will compare this treatment to a sham procedure to assess its effectiveness.

Knee Osteoarthritis>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

Juvenile Idiopathic Arthritis: Bimekizumab Study

We are studying the safety and how bimekizumab moves in the body for children aged 2 to under 18 with certain types of juvenile idiopathic arthritis. This research aims to help improve treatment options for these young patients.

Juvenile Arthritis and Related Conditions6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePediatricsRheumatology

Non-Small Cell Lung Cancer: Neoadjuvant and Adjuvant Treatment Study

We are studying a new treatment approach for patients with resectable non-small cell lung cancer to see if it improves tumor response and safety before and after surgery.

Non-small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Metastatic Colorectal Cancer: Tinzaparin for Blood Clot Prevention

We are studying whether tinzaparin can help prevent blood clots in patients with metastatic colorectal cancer starting their first line of treatment. This may help reduce the risk of complications related to blood clots.

Metastatic Colorectal CancerThromboembolic Event>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyOncology

Myeloid Malignancies: BGB-11417 Study

We are testing a new drug, BGB-11417, in combination with azacitidine for patients with myeloid malignancies. The goal is to find the safest dose and see how well it works against the disease.

Myeloid MalignanciesSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Diabetic Retinopathy: BI 764524 Treatment Study

We are testing whether the new treatment BI 764524 can improve eye health in people with diabetic retinopathy. The study will compare its effects to a placebo to see if it helps prevent serious vision problems.

Diabetic Retinopathy6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesEndocrinologyOphthalmology

Advanced Lung Cancer: Adagrasib and Pembrolizumab Study

We are testing a new treatment combining adagrasib with pembrolizumab for patients with advanced non-small cell lung cancer with a KRAS G12C mutation. The goal is to see if this combination works better than pembrolizumab alone.

Advanced Non-Small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Childhood Renal Tumors: Comparing Chemotherapy Treatments

We are studying two chemotherapy combinations for children with stage IV renal tumors to see which one works better and has fewer side effects. This research aims to improve treatment outcomes for young patients.

Nephroblastoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesNephrologyOncologyPediatrics

High-Grade Glioma in Children: Larotrectinib Treatment

We are studying the effects of larotrectinib on young children with newly diagnosed high-grade glioma that has an NTRK fusion. The trial will help us understand how well it works and its safety when used alone or with chemotherapy.

High Grade Glioma (HGG)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Hidradenitis Suppurativa: Secukinumab Treatment Study

We are investigating the long-term effects of secukinumab on people with moderate to severe hidradenitis suppurativa. This study will help us understand its safety and effectiveness compared to a placebo.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology